摘要
Ischemic stroke is most commonly caused by vascular occlusion due to thrombosis or arterial embolism. Recently, thrombolysis has been used with increasing frequency for the treatment of acute ischemic stroke. Among the drugs used for thrombolysis, only recombinant tissue plasminogen activator is widely accepted internationally （Albers et al., 2008）. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke. Pro-uro- kinase is the precursor of urokinase. Compared with urokinase, pro-uroki- nase has greater ability to dissolve thrombus and is safer to use.
Ischemic stroke is most commonly caused by vascular occlusion due to thrombosis or arterial embolism. Recently, thrombolysis has been used with increasing frequency for the treatment of acute ischemic stroke. Among the drugs used for thrombolysis, only recombinant tissue plasminogen activator is widely accepted internationally （Albers et al., 2008）. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke. Pro-uro- kinase is the precursor of urokinase. Compared with urokinase, pro-uroki- nase has greater ability to dissolve thrombus and is safer to use.
